0.44
+0.017(+4.00%)
Currency In USD
| Previous Close | 0.43 |
| Open | 0.47 |
| Day High | 0.48 |
| Day Low | 0.42 |
| 52-Week High | 2.84 |
| 52-Week Low | 0.38 |
| Volume | 28.02M |
| Average Volume | 5.99M |
| Market Cap | 148.87M |
| PE | -0.98 |
| EPS | -0.45 |
| Moving Average 50 Days | 0.57 |
| Moving Average 200 Days | 0.63 |
| Change | 0.02 |
If you invested $1000 in Sangamo Therapeutics, Inc. (SGMO) 10 years ago, it would be worth $48.78 as of December 02, 2025 at a share price of $0.442. Whereas If you bought $1000 worth of Sangamo Therapeutics, Inc. (SGMO) shares 5 years ago, it would be worth $44.33 as of December 02, 2025 at a share price of $0.442.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy
GlobeNewswire Inc.
4 hours ago
RICHMOND, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ST-503, an investigati
Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease
GlobeNewswire Inc.
Nov 21, 2025 1:05 PM GMT
RICHMOND, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has accepted Sangamo’s request for a rolling submission and
Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call
GlobeNewswire Inc.
Oct 30, 2025 8:01 PM GMT
RICHMOND, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the company has scheduled the release of its third quarter 2025 financial results before the market open